Founded in July 2006, Shandong Huaxipharm Co., LTD is a modern private pharmaceutical group co-invested by Beijing Huaxipharm Co., LTD, it covers 78,000 square meters with a total invest more than 120 million RMB, specializing in the development, production and marketing of generic and proprietary branded drugs as well as active pharmaceutical ingredients.



Shandong Huaxipharm acting as a leading edge company of drug R&D technologies, dedicates to achieving the perfect combination of scientific research and market by continuously developing independent intellectual property rights new drugs,will provide comprehensive, professional quality products and services to serve the total human social.



Currently, Shandong Huaxipharm has established API plant conform to GMP,R8D Lab,QC center and modern Storage with Preparation Plant under construction including injections, tablets, capsules, granules lines. Over 20 products have got the clinical study certificate from SFDA.



The company sets its core R&D centre in Beijing with more than 60 employees among whom 90% have bachelor above degree, and hundreds of consultants in R&D, production, clinical, management and invest areas. R&D centre has successfully developed reputed cooperation with many well-known pharmaceutical companies, universities, research institutions and hospitals.



Huaxipharm Group specializing in developing new drug focuses on neuroscience, endocrine disorders, cancer, infectious diseases, cardiovascular diseases, and inflammation therapeutic area. Long-term extensive cooperation has been maintained with many international enterprises and more than 60 local companies.



With the strength in strong technical support and integration of rich resources, Huaxi HuaxiPharma Group and Shandong HuaxiPharma rising rapidly for specialization and industrialization, continuing to promote innovation in China's medical technology market, pioneering the future of medicine!